Low levels of a clot-busting protein may explain why some people are at higher risk of blood-clotting disorders, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Scientists have made major advances in understanding and developing treatments for many cancers by identifying genetic mutations that drive the disease. Now a team led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and the New York Genome Center (NYGC) has developed a machine learning technique for detecting other modifications to DNA that have a similar effect.
Patients with gynecologic cancers who have Medicaid coverage are more likely to feel increased financial distress, anxiety about their cancer and increased general anxiety during the pandemic if their annual income is less than $40,000, according to a new study from Weill Cornell Medicine investigators.
Molecular "bookmarks," which allow cells to retain their characteristics during cell division, ensure fast reactivation of critical cell identity genes after cell division, according to investigators at Weill Cornell Medicine.
Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, has been awarded a four-year, $600,000 Distinguished Scientist grant by the Sontag Foundation to study the diversity of cell types within brain cancers called gliomas.
Dr. Dan Landau, an associate professor of medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, has been named a 2020 Vallee Scholar by the Vallee Foundation.
With COVID-19 limiting resources and presenting logistical challenges for elective treatments, Weill Cornell Medicine and NewYork-Presbyterian clinicians offer guidance on treating cancer in three recently published papers.
When COVID-19 first appeared in NYC hospitals, Weill Cornell Medicine and NewYork-Presbyterian physicians and scientists documented early observations of clinical and pathological characteristics in two publications.
Preclinical work suggests the targeted drug palbociclib may boost the effectiveness of chemotherapy in pancreatic cancer if the two treatments are given in the right sequence.
Gene mutations detected in blood may predict risk of one of the most common forms of adult leukemia a decade before patients are diagnosed with the disease, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
